1. Search Result
Search Result
Results for "

BMS202

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

MCE Kits

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19745
    BMS-202
    Maximum Cited Publications
    25 Publications Verification

    PD-1/PD-L1 Apoptosis Cancer
    BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .
    BMS-202
  • HY-19745A
    N-deacetylated BMS-202
    1 Publications Verification

    PD-1/PD-L1 Cancer
    N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.
    N-deacetylated BMS-202
  • HY-19745B
    BMS-202 hydrochloride
    Maximum Cited Publications
    25 Publications Verification

    PD-1/PD-L1 Apoptosis Cancer
    BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity .
    BMS-202 hydrochloride
  • HY-150839

    Ligands for E3 Ligase Cancer
    E3 ligase Ligand PG is a E3 ligase ligand that can be used in the recruitment of CRBN protein. E3 ligase Ligand PG exhibits potent binding activity with CRBN (IC50 of 2.191 μM). E3 ligase Ligand PG can be connected to the BMS-202 (HY-19745) by a linker to form PROTAC, PROTAC PD-L1 degrader-1 (HY-163757) .
    E3 ligase Ligand PG
  • HY-182980

    Target Protein Ligand-Linker Conjugates PD-1/PD-L1 Cancer
    N-(8-Carboxyoctanoyl)-deacetyl BMS-202 is a target protein ligand-linker conjugate. N-(8-Carboxyoctanoyl)-deacetyl BMS-202 contains the target protein PD-1/PD-L1 ligand and a PROTAC linker. N-(8-Carboxyoctanoyl)-deacetyl BMS-202 can be used for the synthesis of PROTAC PD-L1 Degrader-3 (HY-182959) .
    N-(8-Carboxyoctanoyl)-deacetyl BMS-202
  • HY-143305

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC50 value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .
    PD-1/PD-L1-IN-25
  • HY-172874

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
    TDO-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: